Table 1 Baseline patient characteristics. ECF, 5-fluorouracil, cisplatin, and epirubicin; TACE, trans-arterial chemoembolization; RFA, radiofrequency ablation; MKIs, multi-kinase inhibitors; HBV, Hepatitis B virus; HCV, Hepatitis C virus.
Variables | ECF chemotherapy (n = 48) |
|---|---|
Age, Median (Range) | 55 (35–84) |
Gender, n (%) Male Female | 37 (77.1) 11 (22.9) |
Previous local treatment, n (%) Surgery TACE Radiotherapy RFA | 23 (47.9) 38 (79.2) 27 (56.2) 11 (22.9) |
Prior systemic therapy, n (%) None Sorafenib Other oral MKIs Regorafenib Cabozantinib Lenvatinib Immune checkpoint inhibitor | 7 (14.6) 36 (75.0) 14 (29.2) 11 (22.9) 4 (8.3) 3 (6.2) 10 (20.8) |
Prior systemic therapy lines, n (%) None or one Two or more | 36 (75.0) 12 (25.0) |
Etiology, n (%) HBV HCV Others | 42 (87.5) 1 (2.1) 6 (12.5) |
Child-Pugh Score, n (%) A (5–6) B (7) | 47 (97.9) 1 (2.1) |
Vascular invasion, n (%) Yes No | 7 (14.6) 41 (85.4) |
Extrahepatic spread, n (%) Yes No | 47 (97.9) 1 (2.1) |
Number of organs involved, n (%) 0–1 ≥ 2 | 23 (47.9) 25 (52.1) |
Site of metastatic lesions, n (%) Lung Distant lymph node Bone Peritoneum | 37 (77.1) 14 (29.2) 15 (31.2) 10 (20.8) |
Baseline α-fetoprotein, n (%) < 400 ng/mL ≥ 400 ng/mL | 25 (52.1) 23 (47.9) |
